


To: Fax No. (571) 273-8300


Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**RECEIVED**  
**CENTRAL FAX CENTER**  
**AUG 08 2005**

<b>TRANSMITTAL FORM</b>  <i>(to be used for all correspondence after initial filing)</i>		Application Number	10/773,083
		Filing Date	02/04/2004
		First Named Inventor	Daniel J. CUA
		Art Unit	1615
		Examiner Name	K. Chong
Total Number of Pages in This Submission	9	Attorney Docket Number	DX06023 US 01

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form (In duplicate) <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<b>Remarks:</b> 1. Response to Restriction Requirement (4 pages) 2. Preliminary Amendment (4 pages)		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual	Sheela Mohan-Peterson, Reg. No. 41,201 DNAX Research, Inc. 901 California Ave. Palo Alto, CA 94304-1104
Signature	
Date	8-Aug-2005

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO, Fax Number (571) 273-8300, or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date indicated below:			
Typed or printed	Melanie Lyons		
Signature		Date	8-8-05

RECEIVED  
CENTRAL FAX CENTER  
AUG 08 2005

Attorney Docket: DX06023 US 01

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In Re application of:

Daniel J. CUA, et al.

Application No.: 10/773,083

Filed: February 4, 2004

For: **USES OF MAMMALIAN  
CYTOKINE; RELATED  
REAGENTS**

Examiner: K. Chong

Art Unit: 1615

Conf. No.: 3286

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on August 8, 2005

by:

  
MELANIE LYONS

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**RESPONSE TO RESTRICTION REQUIREMENT**

Sir:

This is a response to the Restriction Requirement dated July 8, 2005.

**I. Restriction Requirement**

The Examiner restricted the application into 17 separate inventions:

- I. Claims 1, 2, 3, 4, 5 and 8-10, drawn to a method of treating an IL-23 mediated disorder comprising administering an effective amount of a nucleic acid agonist of IL-23, classifiable in class 514, subclass 44.
- II. Claims 1, 2, 3, 4, 5, 8-10, 12, 13 and 15, drawn to a method of treating an IL-23 mediated disorder comprising administering an effective amount of a nucleic acid antagonist of IL-23 wherein the antagonist inhibits activation of a resident microglial cell, classifiable in class 514, subclass 44.
- III. Claims 1, 2, 3, 4, 5, 8-10, 12, 13 and 16-17, drawn to a method of treating an IL-23 mediated disorder comprising administering an effective amount of a nucleic acid antagonist of IL-23 wherein the antagonist inhibits expression of a macrophage, classifiable in class 514, subclass 44.

- IV. Claims 1, 2, 3, 4 and 8-10, drawn to a method of treating an IL-23 mediated disorder comprising administering an effective amount of a small molecule agonist of IL-23, classifiable in class 514, subclass 44.
- V. Claims 1, 2, 3, 4, 8-10, 12, 13 and 15, drawn to a method of treating an IL-23 mediated disorder comprising administering an effective amount of a small molecule antagonist of IL-23 wherein the antagonist inhibits activation of a resident microglial cell, classifiable in class 514, subclass 44.
- VI. Claims 1, 2, 3, 4, 8-10, 12, 13 and 16-17, drawn to a method of treating an IL-23 mediated disorder comprising administering an effective amount of a small molecule antagonist of IL-23 wherein the antagonist inhibits expression of a macrophage, classifiable in class 514, subclass 44.
- VII. Claims 1, 2, and 6-10, drawn to a method of treating an IL-23 mediated disorder comprising administering an effective amount of an antigen binding fragment of an antibody or a soluble receptor agonist of IL-23, classifiable in class 514, subclass 44.
- VIII. Claims 1, 2, 6-10, 12, 13 and 15, drawn to a method of treating an IL-23 mediated disorder comprising administering an effective amount of an antigen binding fragment of an antibody or a soluble receptor agonist of IL-23 wherein the antagonist inhibits activation of a resident microglial cell, classifiable in class 514, subclass 44.
- IX. Claims 1, 2, 6-10, 12, 13 and 16-17, drawn to a method of treating an IL-23 mediated disorder comprising administering an effective amount of an antigen binding fragment of an antibody or a soluble receptor agonist of IL-23 wherein the antagonist inhibits expression of a macrophage, classifiable in class 514, subclass 44, and subject to a further restriction.
- X. Claims 1, 2, 3, 4, 5 and 8-13, drawn to a method of treating an IL-23 mediated disorder comprising administering an effective amount of a nucleic acid agonist of IL-23 and a cytokine, classifiable in class 514, subclass 44, and subject to a further restriction.
- XI. Claims 1, 2, 3, 4, 5 and 8-13, drawn to a method of treating an IL-23 mediated disorder comprising administering an effective amount of a nucleic acid agonist of IL-23 and a cytokine, classifiable in class 514, subclass 44, and subject to a further restriction.
- XII. Claims 1, 2, 4 and 8-13, drawn to a method of treating an IL-23 mediated disorder comprising administering an effective amount of a small molecule agonist of IL-23 and a cytokine, classifiable in class 514, subclass 44, and subject to a further restriction.
- XIII. Claims 1, 2, 4, and 8-13, drawn to a method of treating an IL-23 mediated disorder comprising administering an effective amount of a small molecule antagonist of IL-23 and a cytokine, classifiable in class 514, subclass 44, and subject to a further restriction.

- XIV. Claims 1, 2, and 6-13, drawn to a method of treating an IL-23 mediated disorder comprising administering an effective amount of an antigen binding fragment of an antibody or a soluble receptor agonist of IL-23 and a cytokine, classifiable in class 514, subclass 44, and subject to a further restriction.
- XV. Claims 1, 2, and 6-13, drawn to a method of treating an IL-23 mediated disorder comprising administering an effective amount of an antigen binding fragment of an antibody or a soluble receptor antagonist of IL-23 and a cytokine, classifiable in class 514, subclass 44, and subject to a further restriction.
- XVI. Claims 18-19, drawn to a purified or isolated IL-17 producing CD4+ T cell, classifiable in class 435, subclass 326.
- XVII. Claim 20, drawn to a method of generating an IL-17 producing CD4+ cell, classifiable in class 435, subclass 326.

Applicants provisionally elect Group IX, Claims 1, 2, 6-10, 12, 13, 16, and 17 whose claims are drawn method of treating an IL-23 mediated disorder comprising administering an effective amount of an antigen binding fragment of an antibody or a soluble receptor agonist of IL-23 wherein the antagonist inhibits expression of a macrophage, classifiable in class 514, subclass 44, as discussed in the present Restriction Requirement.

The Examiner further states that if Groups X-XIII are elected, further restriction of Claim 11 is required. This is also mentioned in the listing of the Groups for elected Group IX. Applicants point out that Group IX does not encompass Claim 11, and therefore believe that this group does not require further restriction.

Applicants also submit an accompanying preliminary amendment to assist the Examiner during examination.

Applicants will address the issue of inventorship for the elected claims and amend inventorship appropriately if the elected restriction is made final.

Applicants reserve the right to file subsequent applications claiming the non-elected subject matter and do not waive any of their rights or abandon any non-elected subject matter. Since Applicants have fully and completely responded to the Restriction Requirement and have made the required election, this application is now in order for early action.


If the Examiner believes that a telephone conference would aid the prosecution of this case in any way, please call the undersigned.

The Commissioner is hereby authorized to charge the requisite fee to DNAX Deposit Account 04-1239. Please charge any additional fees or credit overpayment to DNAX Deposit Account No. 04-1239.

Respectfully submitted,

Date: 8-Aug-2005

By:

  
Sheela Mohan-Peterson,  
Reg. No. 41,201  
Attorney for Applicants

**Customer No. 028008**  
DNAX Research, Inc.  
901 California Avenue  
Palo Alto, CA 94304-1104  
Telephone (Switchboard): (650) 496-6400  
Telephone No. (Direct): (650) 496-1244  
Facsimile No.: (650) 496-1200